# Estimating the outcome disparities in BIPOC and economically-disadvantages patients with systemic lupus erythematosus (SLE)

### Background

- Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous presentation and progression, posing significant treatment challenges.
- Despite medical advances, SLE's burden disproportionately affects the BIPOC population and individuals of lower socioeconomic status.

### Objectives

• This study aims to provide an understanding of SLE care disparities, examining mortality rates, treatment accessibility, and the impact of social determinants of health.

### Methods

- Our study involved a literature search on PubMed, spanning from 2018 to 2023. We combined key terms related to SLE, Medicaid, health disparities, and treatment patterns, aiming to collate studies addressing treatment disparities in minority and economically-disadvantaged SLE patients in the U.S.
- There were exclusion criteria for age, region, and context.

# MOCRE

Bruce CM Wang, PhD – Progentec Diagnostics, Inc and Value Genome, LLC

After applying the exclusion criteria, the search re
Prevalence <sup>1</sup>
• The prevalence of SLE was 195 per 100,000, v
Mortality <sup>2</sup>
• The literature found notable disparities in SL
socioeconomic individuals.
Hospitalization <sup>3</sup>
• Hospitalization trends showed an increase in A
similar trends in Hispanic and Asian patients.
Disease duration <sup>4</sup>
• A significant difference was noted in SLE dis-
Whites (8 years).
Complications <sup>5</sup>
• In SLE patients, the literature showed an incre
2.76) SLE patients compared to White patients
Table 1. Summary of different disparities associated wit
Disparity Factor
Race/Ethnicity
Socioeconomic Status
Gender
Socioeconomic Factor
Financial Strain High
Healthcare Access
Disparity Factor
Race/Ethnicity
Disparity Factor
Race/Ethnicity
Conclusion

• This study underscores significant healt equity issues in SLE treatment, especiall affecting BIPOC and low-income population Healthcare systems and policies must b restructured to provide equitable access an treatment, considering the social, economic and cultural contexts of SLE patients.

### Results

esulted in 43 relevant studies.

with greater prevalence observed in the US South, African American population, and females.

E mortality rates, with increased mortality in African American, Hispanic American, and low

African American patient hospitalizations from 37.7% to 44.7% over two decades, alongside

sease duration, notably greater in African Americans (15 years) compared with non-Hispanic

ease in risk of severe COVID-19 outcomes in African American (OR 2.73) and Hispanic (OR

## th SLE Impact on Mortality African American and Hispanic origin associated with increased mortality Low socioeconomic status linked to higher mortality Male sex correlated with increased mortality Impact on Disease Management and Outcomes h financial strain predicts new-onset depression and affects patient-reported outcomes Poor access linked to delays in diagnosis and treatment Impact on Hospitalization Increased hospitalization rate among African American/Hispanic patients **COVID-19** Complications Increased risk of severe COVID-19 among African American and Hispanic patients

			Referenc
th		<ol> <li>Grabich, S., Farrelly, E., Ortmann, R., Pollack, M., &amp; Wu, S. S. (20 cohort study from the Medical Expenditure Panel Survey (MEPS) 2 <u>2021-000640</u></li> <li>Ocampo-Piraquive, V., Nieto-Aristizábal, I., Cañas, C. A., &amp; Tobe interventions. Expert review of clinical immunology, 14(12), 1043–1</li> <li>Edigin, E., Trang, A., Ojemolon, P. E., Eseaton, P. O., Shaka, H., K.</li> </ol>	Grabich, S., Farrelly, E., Ortmann, R., Pollack, M., & Wu, S. S. (2022). Real-wor cohort study from the Medical Expenditure Panel Survey (MEPS) 2016-2018. Lt 2021-000640
ly			Ocampo-Piraquive, V., Nieto-Aristizábal, I., Cañas, C. A., & Tobón, G. J. (20)
lS.			Interventions. Expert review of clinical immunology, 14(12), 1043–1053. <u>https://</u> Edigin, E., Trang, A., Ojemolon, P. E., Eseaton, P. O., Shaka, H., Kichloo, A., Ba
be			(2023). Longitudinal trends of systemic lupus erythematous hospitalizations <i>rheumatology</i> , 42(3), 695–701. https://doi.org/10.1007/s10067-022-06418-2
nd		4.	Sandhu, V. K., Teh, P., Zakhary, B., & Liu, J. (2020). The Southern California L territory <i>Lypus</i> 29(10) 1277–1281. https://doi.org/10.1177/0961203320935172
с,		5.	Ugarte-Gil, M. F., Alarcón, G. S., Seet, A. M., Izadi, Z., Montgomery, A. D., Duar J. A., Hsu, T. Y., D'Silva, K. M., Patel, N. J., Sirotich, E., Liew, J. W., Hausmann, J Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic L
			The author expresses gratitude to Francis Osowik and Youssef Solin

International Society for Pharmacoeconomics and Outcomes Research (ISPOR); Atlanta, GA; May 5 – 8, 2024

#### Poster number: HPR38

### :es

orld burden of systemic lupus erythematosus in the USA: a comparative upus science & medicine, 9(1), e000640. <u>https://doi.org/10.1136/lupus-</u>

018). Mortality in systemic lupus erythematosus: causes, predictors and /doi.org/10.1080/1744666X.2018.1538789

Bazuaye, E. M., Okobia, N. O., Okobia, R. I., Sandhu, V., & Manadan, A. in the United States: a two-decade population-based study. Clinical

Lupus Registry: I. Baseline characteristics of lupus patients in uncharted

rte-García, A., Gilbert, E. L., Valenzuela-Almada, M. O., Wise, L., Sparks, J. S., Sufka, P., Grainger, R., Bhana, S., Wallace, Z., ... Yazdany, J. (2023). Lupus Erythematosus Patients From the United States: Data From the 60. https://doi.org/10.1002/acr.25039

man for their invaluable assistance in conducting the research.